Navigation Links
Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis

WOBURN, Mass., April 14 /PRNewswire/ -- Intrinsic Therapeutics, Inc. announced today that it has received a CE mark for its Barricaid(R) anular prosthesis for use in reconstructing soft tissues of the spine. The CE mark gives Intrinsic approval to distribute the Barricaid throughout the European Union and in other countries that recognize the CE mark.

(Logo: )

"We are very pleased with receiving the CE mark and believe that this event reflects, in part, on the very positive clinical results in our current, prospective clinical study of the Barricaid anular prosthesis," stated Barry Sands, Vice President Regulatory, Clinical, and Quality Affairs. The Barricaid ( is a revolutionary partial disc prosthesis that enables surgeons to directly reconstruct the anulus of the intervertebral disc in patients with lumbar disc herniations and sciatica as part of a standard, minimal access discectomy procedure. More than 500,000 discectomies are performed worldwide each year.

"This approval gives Intrinsic the opportunity to offer surgeons, patients, and payers the potential for a truly better outcome in the treatment of lumbar disc herniation, the most common degenerative condition of the spine," stated Greg Lambrecht, President & CEO. "The Barricaid and its approval in the European Union is the culmination of years of extensive pre-clinical and clinical development to address this fundamental, unmet need in spine surgery. Surgeons have tried many different techniques over the years to repair the anulus including sutures, glues, and clips with very limited success. The Barricaid offers a new surgical strategy by reconstructing the anulus and anchoring it to the vertebral body for a more secure solution. Intrinsic and the surgeons we serve are very excited by the positive results from the initial clinical study of the Barricaid that helped us reach this important milestone."

About Intrinsic Therapeutics

Intrinsic Therapeutics is dedicated to treating soft-tissue injuries of the spine. Intrinsic's Barricaid anular reconstructive products are used during discectomy to definitively close defects in the posterior anulus. By restoring anular competence, the Barricaid family of products may reduce the risk of recurrent herniation while maintaining disc height and biomechanics.

    Scott LeBlanc                               Tom Guest
    Director Finance                            VP Sales & Marketing
    Intrinsic Therapeutics, Inc.                Intrinsic Therapeutics, Inc.
    781-932-0222 ext. 173                       781-932-0222 ext. 133

SOURCE Intrinsic Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
(Date:10/13/2017)... Little Rock, AR (PRWEB) , ... October 13, ... ... owned firm with locations throughout Arkansas that offers insurance and financial preparation services, ... to benefit the Rock City Rescue organization. , Rock City Rescue is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
Breaking Medicine Technology: